Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Alimera Sciences stock
Learn how to easily invest in Alimera Sciences stock.
Alimera Sciences is a drug manufacturers-specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 145 staff and has a trailing 12-month revenue of around $54.1 million.
How to buy Alimera Sciences stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALIM. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Alimera Sciences stock price (NASDAQ: ALIM)Use our graph to track the performance of ALIM stocks over time.
Alimera Sciences shares at a glance
|Latest market close||$2.70|
|52-week range||$2.03 - $7.92|
|50-day moving average||$2.97|
|200-day moving average||$5.02|
|Wall St. target price||$10.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.97|
Buy Alimera Sciences stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Alimera Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alimera Sciences price performance over time
|1 week (2023-02-01)||-4.26%|
|1 month (2023-01-06)||-4.59%|
|3 months (2022-11-08)||-46.32%|
|6 months (2022-08-08)||-62.40%|
|1 year (2022-02-04)||-37.21%|
|2 years (2021-02-08)||-65.95%|
|3 years (2020-02-07)||6.9299|
|5 years (2018-02-07)||16.95|
Alimera Sciences financials
|Revenue TTM||$54.1 million|
|Gross profit TTM||$52 million|
|Return on assets TTM||-14.84%|
|Return on equity TTM||0%|
|Market capitalisation||$18.9 million|
TTM: trailing 12 months
Alimera Sciences share dividends
We're not expecting Alimera Sciences to pay a dividend over the next 12 months.
Have Alimera Sciences's shares ever split?
Alimera Sciences's shares were split on a 1:15 basis on 14 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.
Alimera Sciences share price volatility
Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $2.03 up to $7.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.3645. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alimera Sciences overview
Alimera Sciences, Inc. , a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences in the news
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
Frequently asked questionsWhat percentage of Alimera Sciences is owned by insiders or institutions?
Currently 19.997% of Alimera Sciences shares are held by insiders and 30.57% by institutions. How many people work for Alimera Sciences?
Latest data suggests 145 work at Alimera Sciences. When does the fiscal year end for Alimera Sciences?
Alimera Sciences's fiscal year ends in December. Where is Alimera Sciences based?
Alimera Sciences's address is: 6310 Town Square, Alpharetta, GA, United States, 30005 What is Alimera Sciences's ISIN number?
Alimera Sciences's international securities identification number is: US0162592028 What is Alimera Sciences's CUSIP number?
Alimera Sciences's Committee on Uniform Securities Identification Procedures number is: 016259202
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert